Hello @Manufacturer and @Agency .

Please find uploaded the completed Tag report and CEI report for Q4 of 2023. Please let us know if you have any questions.

Have a great week.

Hey @constance

Always happy to have more examples to discuss. If you’d like to send examples for the group to discuss, please email them to me at jenniferc@paab.ca.

What we would require is:
• Confirmation from the sponsor that the content can be discussed and shared with the committee
• Confirmation from the sponsor that all content discussed can be shared externally as part of training documents
• Any information you can share about the campaign such as “what are the primary and secondary messages the campaign hopes to convey”
• If the creative went through iterations, provide the iterations (iterations with PAAB or outside of PAAB such as through the internal Canadianization process or within the agency).
• If you have internally developed creative that was not part of a sponsor project that you think would make for good discussions, we can look at those as well

The committee will not be evaluating the merits of any past decisions or evidence and in most cases the discussions will be brand agnostic so that the discussion stays focused on assessing creative elements.

As the committee is meeting in early January, we'd encourage sending content before then. 🙂

@jennifer-carroll Thank you for the information.

@costeap Absolutely we can add guidance on why tags were deemed invalid. Great suggestion. We’ll add it in to Q3. Thank you for the feedback.

Hello @dmauri

PAAB practice has been to accept communications from formulary bodies to the manufacturer which confirm listing and criteria in the absence of published coverage criteria. In the absence of these letters, we have accepted an attestation from the sponsor that confirms the EAP listing and that the government/ministry has no objection to the marketing of this criteria. The client can proceed with submitting pieces which communicate the listing and criteria.